SG11201705583XA - Cxcr4 binding molecules - Google Patents

Cxcr4 binding molecules

Info

Publication number
SG11201705583XA
SG11201705583XA SG11201705583XA SG11201705583XA SG11201705583XA SG 11201705583X A SG11201705583X A SG 11201705583XA SG 11201705583X A SG11201705583X A SG 11201705583XA SG 11201705583X A SG11201705583X A SG 11201705583XA SG 11201705583X A SG11201705583X A SG 11201705583XA
Authority
SG
Singapore
Prior art keywords
binding molecules
cxcr4 binding
cxcr4
molecules
binding
Prior art date
Application number
SG11201705583XA
Inventor
Michael Foley
Andrew Pow
Katherine Griffiths
Samantha Cobb
Katerina Viduka
Original Assignee
Adalta Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015900054A external-priority patent/AU2015900054A0/en
Application filed by Adalta Pty Ltd filed Critical Adalta Pty Ltd
Publication of SG11201705583XA publication Critical patent/SG11201705583XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
SG11201705583XA 2015-01-09 2016-01-08 Cxcr4 binding molecules SG11201705583XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015900054A AU2015900054A0 (en) 2015-01-09 CXCR4 binding molecules
PCT/AU2016/050005 WO2016109872A1 (en) 2015-01-09 2016-01-08 Cxcr4 binding molecules

Publications (1)

Publication Number Publication Date
SG11201705583XA true SG11201705583XA (en) 2017-08-30

Family

ID=56355354

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202111844VA SG10202111844VA (en) 2015-01-09 2016-01-08 Cxcr4 binding molecules
SG11201705583XA SG11201705583XA (en) 2015-01-09 2016-01-08 Cxcr4 binding molecules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202111844VA SG10202111844VA (en) 2015-01-09 2016-01-08 Cxcr4 binding molecules

Country Status (12)

Country Link
US (2) US10538596B2 (en)
EP (2) EP3242685B1 (en)
JP (3) JP6863897B2 (en)
CN (2) CN114478773A (en)
AU (3) AU2016206191B2 (en)
CA (1) CA2973317A1 (en)
DK (1) DK3242685T3 (en)
ES (1) ES2924394T3 (en)
HR (1) HRP20220860T1 (en)
LT (1) LT3242685T (en)
SG (2) SG10202111844VA (en)
WO (1) WO2016109872A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242685B1 (en) * 2015-01-09 2022-05-04 AdAlta Limited Cxcr4 binding molecules
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
EP3535293A1 (en) 2016-11-07 2019-09-11 Crossbeta Biosciences B.V. Novel amyloid beta oligomer specific binding molecule
EP3568160A1 (en) * 2017-01-16 2019-11-20 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Improved multi tyrosine kinase inhibitor therapy
KR20200103018A (en) 2017-12-19 2020-09-01 주식회사 지피씨알 GPCR heteromer inhibitors and uses thereof
WO2020205836A1 (en) * 2019-04-02 2020-10-08 Eli Lilly And Company Methods of selecting and detecting binding peptides
TW202110436A (en) * 2019-05-17 2021-03-16 南韓商Ｇｐｃｒ醫療公司 Gpcr heteromer inhibitors and uses thereof
JP7365674B2 (en) * 2019-08-29 2023-10-20 国立大学法人 長崎大学 Aspergilloma model non-human animal
CN110804100A (en) * 2019-11-01 2020-02-18 中国人民解放军陆军特色医学中心 Fusion polypeptide, application of fusion polypeptide in enhancing homing capability and anti-apoptosis capability of stem cells and pharmaceutical composition
WO2023092177A1 (en) * 2021-11-23 2023-06-01 Adalta Limited Rank-l binding molecules
CN114533884A (en) * 2022-04-20 2022-05-27 澳门大学 Medicine for combined treatment of cancer and application of S100A9-CXCL12 signal inhibitor

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439A (en) 1846-04-04 Improvement in cleansing fish-oils
US196A (en) 1837-05-15 Machine for mowing and heaping grain
US4475A (en) 1846-04-25 Henry johnson
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5206154A (en) 1985-01-28 1993-04-27 Xoma Corporation Method of producing cecropins by microbiological techniques
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5215896A (en) 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
SE8804074D0 (en) 1988-11-10 1988-11-10 Pharmacia Ab SENSOR UNIT AND ITS USE IN BIOSENSOR SYSTEM
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH08501213A (en) 1992-08-21 1996-02-13 ザ ユニバーシティー オブ ブリティッシュ コロンビア Cationic peptide and method for producing the same
US5648244A (en) 1993-09-27 1997-07-15 President And Fellows Of Harvard College Production, purification, cleavage and use of fusion peptides
US5485277A (en) 1994-07-26 1996-01-16 Physical Optics Corporation Surface plasmon resonance sensor and methods for the utilization thereof
US6037145A (en) 1994-09-07 2000-03-14 Suntory Limited Process for production of protein
US5567301A (en) 1995-03-01 1996-10-22 Illinois Institute Of Technology Antibody covalently bound film immunobiosensor
US5972639A (en) 1997-07-24 1999-10-26 Irori Fluorescence-based assays for measuring cell proliferation
DE19818790A1 (en) 1998-04-27 1999-10-28 Affina Immuntechnik Gmbh Preparation of an immuno-adsorption matrix, useful for diagnostic and therapeutic purposes
ES2198913T5 (en) 1998-05-06 2013-11-18 Genentech, Inc. Protein purification by ion exchange chromatography
US6613548B1 (en) 1998-07-31 2003-09-02 Pierce Biotechnology, Inc. Fusion products containing insoluble proteinaceous tag
US6190908B1 (en) 1998-08-12 2001-02-20 The Scripps Research Institute Modulation of polypeptide display on modified filamentous phage
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6242219B1 (en) 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
AU6267000A (en) 1999-06-30 2001-01-22 Evotec Oai Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
CA2406873A1 (en) 2000-04-25 2001-11-01 Chemicon International, Inc. Cell proliferation assay
WO2002026292A1 (en) 2000-09-28 2002-04-04 Affina Immuntechnik Gmbh Circulatory device for separating substances in bodily fluids, especially blood, and the use of said device
DE60331226D1 (en) 2002-05-24 2010-03-25 Medtronic Inc METHOD AND DNA CONSTRUCTIONS FOR PRODUCING POLYPEPTIDES HAVING HIGH PROFIT
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
WO2005108415A2 (en) * 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
KR20070039911A (en) 2004-06-01 2007-04-13 도만티스 리미티드 Bispecific fusion antibodies with enhanced serum half-life
DK2330121T3 (en) * 2004-06-02 2014-12-15 Adalta Pty Ltd Binding moieties based on shark IgNar domains
WO2007115232A2 (en) 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
WO2007115231A2 (en) 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
HUE027165T2 (en) * 2006-10-02 2016-08-29 Squibb & Sons Llc Human antibodies that bind cxcr4 and uses thereof
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
CN101657715B (en) 2006-11-10 2012-07-25 戴麦里克斯生物科学有限公司 Detection system and uses therefor
WO2008109154A1 (en) 2007-03-08 2008-09-12 Altiris Therapeutics, Inc. Chemokine receptor modulators
JP2011526244A (en) 2008-03-20 2011-10-06 カロラス セラピューティクス， インク． How to treat inflammation
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
CA2742515C (en) 2008-11-04 2017-07-11 Chemocentryx, Inc. 1,4-diazepane modulators of cxcr7
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
JP6541350B2 (en) * 2011-11-09 2019-07-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Treatment of hematologic malignancies with anti-CXCR4 antibody
EP2964332A4 (en) * 2013-03-08 2016-09-14 Curonz Holdings Company Ltd Neural regeneration peptides and uses therefor
EP3242685B1 (en) 2015-01-09 2022-05-04 AdAlta Limited Cxcr4 binding molecules

Also Published As

Publication number Publication date
CN107427574A (en) 2017-12-01
US20200231708A1 (en) 2020-07-23
US11142588B2 (en) 2021-10-12
DK3242685T3 (en) 2022-07-25
US10538596B2 (en) 2020-01-21
JP2018504112A (en) 2018-02-15
JP2020182479A (en) 2020-11-12
CN114478773A (en) 2022-05-13
CN107427574B (en) 2022-02-08
AU2016206191A9 (en) 2017-01-19
HRP20220860T1 (en) 2022-10-14
SG10202111844VA (en) 2021-12-30
WO2016109872A1 (en) 2016-07-14
EP4112077A1 (en) 2023-01-04
CA2973317A1 (en) 2016-07-14
JP6863897B2 (en) 2021-04-21
JP2023015277A (en) 2023-01-31
EP3242685A1 (en) 2017-11-15
LT3242685T (en) 2022-08-25
AU2016206191A1 (en) 2016-12-15
AU2016206191B2 (en) 2017-08-03
AU2019203511B2 (en) 2021-08-12
EP3242685B1 (en) 2022-05-04
EP3242685A4 (en) 2018-07-11
ES2924394T3 (en) 2022-10-06
AU2017254863A1 (en) 2017-11-16
AU2019203511A1 (en) 2019-06-06
JP7212009B2 (en) 2023-01-24
US20180072816A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
IL251891B (en) Binding molecules specific for cd73 and uses thereof
HK1252791A1 (en) Binding molecules with modified j-chain
GB201521858D0 (en) Small molecules
GB201412659D0 (en) Molecules
GB201612520D0 (en) Binding molecules
GB201412658D0 (en) Molecules
SG11201705583XA (en) Cxcr4 binding molecules
EP3506964C0 (en) Binding syringe
IL273641B (en) Binding molecules specific for il-21 and uses thereof
GB201500463D0 (en) Therapeutic molecules
GB201702091D0 (en) Specific binding molecules
GB201500461D0 (en) Therapeutic molecules
GB201522391D0 (en) Antibody molecules
GB2537722B (en) Booklet
GB201508729D0 (en) Binding molecules
AU2015900054A0 (en) CXCR4 binding molecules
GB201618186D0 (en) Binding members
AU364528S (en) Lectern
GB201503832D0 (en) Inamo big book V3
AU363722S (en) Multimedia book
AU363723S (en) Multimedia book
AU363724S (en) Multimedia book
GB201413567D0 (en) Binding surfaces